Manifold Bio

Designs precision biologics using in vivo methods

Boston, Massachusetts, United States

About Manifold Bio

Manifold Bio specializes in creating precision biologics for the pharmaceutical industry, focusing on drug design and development. Their main product is an in vivo drug design platform, which allows for testing drugs within living organisms rather than in laboratory settings. This platform utilizes mCodes™ technology, a unique protein barcoding system that enables the simultaneous study of multiple proteins in one experiment, making it particularly effective for complex biologics. Unlike other companies, Manifold Bio's approach to drug design is distinct because it integrates in vivo testing with advanced protein multiplexing capabilities. The company's goal is to expand their platform and collaborate with other pharmaceutical companies to develop new therapeutics.

Boston, MassachusettsHeadquarters
2020Year Founded
$58.8MTotal Funding
SERIES_ACompany Stage
Biotechnology, HealthcareIndustries
11-50Employees

Risks

Increased competition from companies like Insamo and Infinimmune.
Rapid AI and ML advancements may outpace Manifold Bio's current technology.
Regulatory challenges in in vivo testing could delay product development timelines.

Differentiation

Manifold Bio uses proprietary mCodes™ technology for protein multiplexing in drug design.
Their in vivo drug design platform is the first of its kind globally.
The company specializes in precision biologics, focusing on complex biologics development.

Upsides

Raised $40M in Series A funding, indicating strong market interest.
Their platform could revolutionize in vivo testing by testing multiple molecules simultaneously.
Strategic partnerships with multiple investors enhance growth and development opportunities.